NASDAQ:AVEOAVEO Pharmaceuticals Stock Price, Forecast & News

$7.76

-0.13 (-1.65 %)

(As of 06/3/2020 03:49 PM ET)

Add

Compare

Today's Range

$7.72

Now: $7.76▼

$8.00

50-Day Range

$3.75

MA: $6.87▼

$9.99

52-Week Range

$2.23

Now: $7.76▼

$11.20

Volume416,595 shs

Average Volume840,946 shs

Market Capitalization$124.70 million

P/E Ratio12.71

Dividend YieldN/A

Beta1.69

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
AVEO Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.50, AVEO Pharmaceuticals has a potential upside of 162.7% from its current price of $7.81.
Amount of Analyst Coverage
AVEO Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
AVEO Pharmaceuticals has received 383 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AVEO Pharmaceuticals has received 359 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AVEO Pharmaceuticals has received 51.62% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote “Outperform” if you believe AVEO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AVEO Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AVEO Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVEO Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.50% of the stock of AVEO Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 28.10% of the stock of AVEO Pharmaceuticals is held by institutions.

1.9 Earnings and Valuation

Earnings Growth
Earnings for AVEO Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVEO Pharmaceuticals is 12.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVEO Pharmaceuticals is 12.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.36.
Price to Book Value per Share Ratio
AVEO Pharmaceuticals has a P/B Ratio of 8.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:AVEO

Previous Symbol

CUSIP05358810

CIK1325879

Webwww.aveooncology.com

Phone617-588-1960

Debt

Debt-to-Equity Ratio0.52

Current Ratio1.68

Quick Ratio1.68

Price-To-Earnings

Trailing P/E Ratio12.71

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$28.80 million

Price / Sales4.33

Cash Flow$0.59 per share

Price / Cash Flow13.20

Book Value$0.92 per share

Price / Book8.43

Profitability

EPS (Most Recent Fiscal Year)$0.61

Net Income$9.39 million

Net Margins1.62%

Return on Equity4.28%

Return on Assets0.95%

Miscellaneous

Employees17

Outstanding Shares16,080,000

Market Cap$124.70 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

How has AVEO Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVEO shares have increased by 123.6% and is now trading at $7.8050. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AVEO Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AVEO Pharmaceuticals.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for AVEO Pharmaceuticals.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.02. The biopharmaceutical company had revenue of $0.78 million for the quarter, compared to analyst estimates of $2.25 million. AVEO Pharmaceuticals had a return on equity of 4.28% and a net margin of 1.62%. View AVEO Pharmaceuticals' earnings history.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

Shares of AVEO Pharmaceuticals reverse split before market open on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

4 brokerages have issued 12 month price objectives for AVEO Pharmaceuticals' shares. Their forecasts range from $12.00 to $26.00. On average, they expect AVEO Pharmaceuticals' share price to reach $20.50 in the next twelve months. This suggests a possible upside of 162.7% from the stock's current price. View analysts' price targets for AVEO Pharmaceuticals.

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:

1. According to Zacks Investment Research, "AVEO got a huge boost from the approval for Fotivda in Europe for the first-line treatment of advanced renal cell carcinoma. However, it faced a major setback when it had to delay the new drug application filling for Fotivda in the United States. In September 2019, AVEO announced updated data from the second prespecified analysis of overall survival from the phase III study on Fotivda. The results included an OS hazard ratio of less than one, favoring Fotivda. Failure to receive regulatory approvals or termination of any deal would significantly hurt the stock in future. AVEO receives royalties from Fotivda sales in certain European countries. This is another revenue driver. Shares have underperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings. AVEO has a mixed record earnings surprises in recent quarters." (2/21/2020)
2. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Media coverage about AVEO stock has trended somewhat positive on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,310,000 shares, a decrease of 5.1% from the April 30th total of 1,380,000 shares. Based on an average daily trading volume, of 437,600 shares, the days-to-cover ratio is currently 3.0 days. Approximately 9.7% of the shares of the company are sold short. View AVEO Pharmaceuticals' Current Options Chain.

Who are some of AVEO Pharmaceuticals' key competitors?

Some companies that are related to AVEO Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Amarin (AMRN), Opko Health (OPK), Inovio Pharmaceuticals (INO), Canopy Growth (CGC) and Alibaba Group (BABA).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:

Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
Dr. Michael N. Needle, Chief Medical Officer (Age 59)
Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
Dr. Emile Farhan Ph.D., VP of Technical Operations

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include NEA Management Company LLC (15.70%), BlackRock Inc. (1.45%), Geode Capital Management LLC (0.61%), GSA Capital Partners LLP (0.57%), X Square Capital LLC (0.41%) and WINTON GROUP Ltd (0.36%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris and Peter W Sonsini. View institutional ownership trends for AVEO Pharmaceuticals.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BlackRock Inc., Geode Capital Management LLC, GSA Capital Partners LLP, WINTON GROUP Ltd, X Square Capital LLC, Evercore Wealth Management LLC, and Morgan Stanley. View insider buying and selling activity for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $7.81.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $125.50 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff